ArticleDisease models & mechanisms2018
Nmnat mitigates sensory dysfunction in a
Article in Disease models & mechanisms, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Programmed axon degeneration: mechanism, inhibition and therapeutic potential.Nature reviews. Neuroscience · 2026Review
- ILP4 and InR regulate paclitaxel-induced hypersensitivity differently inMolecular biology of the cell · 2026Article
- Modelling Neural Disorders with theBiomolecules · 2025Review
- A novel isoquinoline mitophagy inducer ameliorates paclitaxel-induced peripheral neuropathy in Drosophila and mouse models.Scientific reports · 2025Article
- PDH Inhibition inBiomedicines · 2025Article
- Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders.Pharmaceuticals (Basel, Switzerland) · 2022Review
- The PINK1 Activator Niclosamide Mitigates Mitochondrial Dysfunction and Thermal Hypersensitivity in a Paclitaxel-InducedBiomedicines · 2022Article
- Cellular Pathogenesis of Chemotherapy-Induced Peripheral Neuropathy: Insights FromFrontiers in pain research (Lausanne, Switzerland) · 2022Review
- Article
- Integrins protect sensory neurons in models of paclitaxel-induced peripheral sensory neuropathy.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Article
- Analyzing chemotherapy-induced peripheral neuropathy in vivo using non-mammalian animal models.Experimental neurology · 2020Review
- PINK1 alleviates thermal hypersensitivity in a paclitaxel-induced Drosophila model of peripheral neuropathy.PloS one · 2020Article
- Review
- PeripheralPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019Article
- Nerve injury drives a heightened state of vigilance and neuropathic sensitization inScience advances · 2019Article
- Chemotherapy-Induced Peripheral Neuropathy and Changes in Cytoskeleton.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is the major dose-limiting side effect of many commonly used chemotherapeutic agents, including paclitaxel. Currently, there are no neuroprotective or effective symptomatic treatments for CIPN. Lack of understanding of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.